Purpose of Review: The aim of this review is to focus on the recent advances in the molecular knowledge of small cell lung cancer (SCLC) and potential promising new treatment strategies, like targeting the DNA damage pathway, epigenetics, angiogenesis, and oncogenic drivers. Recent Findings: In the last few years, the addition of immunotherapy to chemotherapy has led to significant improvements in clinical outcomes in this complex neoplasia. Nevertheless, the prognosis remains dismal. Recently, numerous genomic alterations have been identified, and they may be useful to classify SCLC into different molecular subtypes (SCLC-A, SCLC-I, SCLC-Y, SCLC-P). Summary: SCLC accounts for 10-20% of all lung cancers, most patients have an extensive disease at the diagnosis, and it is characterized by poor prognosis. Despite the progresses in the knowledge of the disease, efficacious targeted treatments are still lacking. In the near future, the molecular characterisation of SCLC will be fundamental to find more effective treatment strategies.

Canova, S., Trevisan, B., Abbate, M., Colonese, F., Sala, L., Baggi, A., et al. (2023). Novel Therapeutic Options for Small Cell Lung Cancer. CURRENT ONCOLOGY REPORTS, 25(11), 1277-1294 [10.1007/s11912-023-01465-7].

Novel Therapeutic Options for Small Cell Lung Cancer

Abbate, MI;Bianchi, SP;Cortinovis, DL
2023

Abstract

Purpose of Review: The aim of this review is to focus on the recent advances in the molecular knowledge of small cell lung cancer (SCLC) and potential promising new treatment strategies, like targeting the DNA damage pathway, epigenetics, angiogenesis, and oncogenic drivers. Recent Findings: In the last few years, the addition of immunotherapy to chemotherapy has led to significant improvements in clinical outcomes in this complex neoplasia. Nevertheless, the prognosis remains dismal. Recently, numerous genomic alterations have been identified, and they may be useful to classify SCLC into different molecular subtypes (SCLC-A, SCLC-I, SCLC-Y, SCLC-P). Summary: SCLC accounts for 10-20% of all lung cancers, most patients have an extensive disease at the diagnosis, and it is characterized by poor prognosis. Despite the progresses in the knowledge of the disease, efficacious targeted treatments are still lacking. In the near future, the molecular characterisation of SCLC will be fundamental to find more effective treatment strategies.
Articolo in rivista - Articolo scientifico
Immunotherapy; PARP inhibitors; SCLC classification; Target therapy;
English
23-ott-2023
2023
25
11
1277
1294
open
Canova, S., Trevisan, B., Abbate, M., Colonese, F., Sala, L., Baggi, A., et al. (2023). Novel Therapeutic Options for Small Cell Lung Cancer. CURRENT ONCOLOGY REPORTS, 25(11), 1277-1294 [10.1007/s11912-023-01465-7].
File in questo prodotto:
File Dimensione Formato  
10281-453859_VoR.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Creative Commons
Dimensione 825.45 kB
Formato Adobe PDF
825.45 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/453859
Citazioni
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
Social impact